PMID- 34093544
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Dendritic Cells: Versatile Players in Renal Transplantation.
PG  - 654540
LID - 10.3389/fimmu.2021.654540 [doi]
LID - 654540
AB  - Dendritic cells (DCs) induce and regulate adaptive immunity through migrating and 
      maturing in the kidney. In this procedure, they can adopt different 
      phenotypes-rejection-associated DCs promote acute or chronic injury renal grafts 
      while tolerogenic DCs suppress the overwhelmed inflammation preventing damage to 
      renal functionality. All the subsets interact with effector T cells and 
      regulatory T cells (Tregs) stimulated by the ischemia-reperfusion procedure, 
      although the classification corresponding to different effects remains 
      controversial. Thus, in this review, we discuss the origin, maturation, and 
      pathological effects of DCs in the kidney. Then we summarize the roles of 
      divergent DCs in renal transplantation: taking both positive and negative stages 
      in ischemia-reperfusion injury (IRI), switching phenotypes to induce acute or 
      chronic rejection, and orchestrating surface markers for allograft tolerance via 
      alterations in metabolism. In conclusion, we prospect that multidimensional 
      transcriptomic analysis will revolute researches on renal transplantation by 
      addressing the elusive mononuclear phagocyte classification and providing a 
      holistic view of DC ontogeny and subpopulations.
CI  - Copyright (c) 2021 Lin, Wang, Liu, Cheng, Deng, Zhu and Chen.
FAU - Lin, Jinwen
AU  - Lin J
AD  - Kidney Disease Center, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Key Laboratory of Kidney Disease Prevention and Control Technology, National Key 
      Clinical Department of Kidney Disease, Institute of Nephrology, Zhejiang 
      University, Hangzhou, China.
AD  - The Third Grade Laboratory under the National State, Administration of 
      Traditional Chinese Medicine, Hangzhou, China.
FAU - Wang, Hongyi
AU  - Wang H
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Liu, Chenxi
AU  - Liu C
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Cheng, Ao
AU  - Cheng A
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Deng, Qingwei
AU  - Deng Q
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Zhu, Huijuan
AU  - Zhu H
AD  - Department of Pathology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Chen, Jianghua
AU  - Chen J
AD  - Kidney Disease Center, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Key Laboratory of Kidney Disease Prevention and Control Technology, National Key 
      Clinical Department of Kidney Disease, Institute of Nephrology, Zhejiang 
      University, Hangzhou, China.
AD  - The Third Grade Laboratory under the National State, Administration of 
      Traditional Chinese Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210519
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Acute Disease
MH  - Allografts
MH  - Animals
MH  - Chronic Disease
MH  - Dendritic Cells/*immunology/*metabolism
MH  - Graft Rejection/immunology
MH  - Graft Survival/immunology
MH  - Humans
MH  - Immune Tolerance
MH  - Immunomodulation
MH  - Immunotherapy
MH  - *Kidney Transplantation
MH  - Reperfusion Injury/etiology/metabolism
MH  - *Transplantation Immunology
PMC - PMC8170486
OTO - NOTNLM
OT  - dendritic cells
OT  - ischemic-reperfusion injury
OT  - rejection
OT  - renal transplantation
OT  - tolerance
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/09/30 06:00
PMCR- 2021/01/01
CRDT- 2021/06/07 05:50
PHST- 2021/01/16 00:00 [received]
PHST- 2021/04/22 00:00 [accepted]
PHST- 2021/06/07 05:50 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.654540 [doi]
PST - epublish
SO  - Front Immunol. 2021 May 19;12:654540. doi: 10.3389/fimmu.2021.654540. eCollection 
      2021.